Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc.

Contributed by: Business Wire

Tags

Pharmaceutical

Finance

General Health

Health

Banking

Professional Services

Vitamins/Supplements

Business

Intercept Pharmaceuticals

More Like This

Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets

Hansa Biopharma Interim Report January-September 2023

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results